中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 10
Oct.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(10): 2093-2101

Efficacy and safety of CA280 cytokine adsorption column in treatment of acute-on-chronic liver failure

DOI: 10.12449/JCH251020

  • First Department of Hepatology，The Ninth Hospital of Nanchang，Nanchang 330000，China

Research funding:

Beijing Liver-Gallbladder Xiangzhao Charity Foundation (iGandanF-1082023-RGG035)

More Information
  • Corresponding author: XIONG Molong， xml86005@163.com （ORCID： 0000-0003-4701-6002）; XIONG Yunfeng， 11614879@qq.com （ORCID： 0000-0001-5189-409X）
  • Received Date: 2025-01-20
  • Accepted Date: 2025-05-22
  • Published Date: 2025-10-25
    Abstract
  •   Objective  To investigate the application of the novel inflammatory factor adsorption column CA280 combined with low-dose plasma exchange （LPE） in patients with acute-on-chronic liver failure （ACLF）.  Methods  A prospective cohort study was designed， and a total of 93 ACLF patients who were admitted to The Ninth Hospital of Nanchang from June 2023 to January 2025 were enrolled and randomly divided into DPMAS+LPE group with 50 patients and CA280+LPE group with 43 patients. In addition to comprehensive medical treatment， the patients in the DPMAS+LPE group received DPMAS and LPE treatment， and those in the CA280+LPE group received CA280 and LPE treatment. The two groups were observed in terms of routine blood test results， liver function parameters， renal function markers， electrolytes， coagulation function parameters， cytokines， adverse events， and 28-day prognosis before surgery （baseline）， during surgery （DPMAS or CA280）， and after surgery （after sequential LPE treatment）. The paired t-test was used for comparison of normally distributed continuous data before and after treatment within each group， and the independent-samples t test was used for comparison between groups； the Wilcoxon signed-rank test was used for comparison of non-normally distributed continuous data before and after treatment within each group， and the Mann-Whitney U test was used for comparison between groups. The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups， and the Spearman test was used for correlation analysis.  Results  After CA280 treatment， the ACLF patients had significant reductions in the levels of cytokines （IL-6， IL-8， IL-10， TNF-α， and IFN-γ）， liver function parameters （ALT， AST， ALP， TBil， DBil， Alb， and glutathione reductase）， and the renal function marker urea nitrogen （all P<0.05）， and in terms of coagulation function parameters， there were significant increases in prothrombin time， activated partial thromboplastin time （APTT）， thrombin time， and international normalized ratio （INR） and significant reductions in prothrombin activity （PTA） and fibrinogen （FIB） （all P<0.05）. Compared with the DPMAS+LPE group， the CA280+LPE group showed better improvements in the serum cytokines IL-8 （Z=-2.63， P=0.009）， IL-10 （Z=-3.94， P<0.001）， and TNF-α （Z=-1.53， P=0.023）， and the two artificial liver support systems had a similar effect in improving liver function （ALT， AST， GGT， GR， TBil， and DBil） （all P >0.05）， but the CA280+LPE group showed a significantly greater reduction in Alb （Z=-2.08， P=0.037）. CA280+LPE was more effective in reducing uric acid （Z=-2.97， P=0.003）. Compared with DPMAS+LPE， CA280+LPE treatment resulted in a significant reduction in INR （Z=-4.01， P<0.001）， a significant increase in APTT （Z=-2.53， P=0.011）， and significant greater increases in PTA （Z=-6.28， P<0.001） and FIB （Z=-3.93， P<0.001）. There were no significant differences in the incidence rates of adverse reactions and the rate of improvement at discharge between the two groups （all P>0.05）. The Spearman correlation analysis showed that IL-6 was significantly correlated with WBC （r=0.22， P=0.042）， TBil （r=0.29， P=0.005）， and FIB （r=-0.33， P=0.003）； IL-8 was positively correlated with APTT （r=0.37， P<0.001） and INR （r=0.25， P=0.013）； TNF-α was significantly correlated with WBC （r=0.40， P<0.001） and TBil （r=0.34， P<0.001）.  Conclusion  Compared with DPMAS， CA280 combined with LPE can effectively clear proinflammatory cytokines and improve liver function in ACLF patients， but it has a certain impact on Alb and coagulation function. This regimen provides a new option for the individualized treatment of ACLF and can improve the short-term prognosis of patients， but further studies are needed to verify its long-term efficacy.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    BR VK, SARIN SK. Acute-on-chronic liver failure: Terminology, mechanisms and management[J]. Clin Mol Hepatol, 2023, 29( 3): 670- 689. DOI: 10.3350/cmh.2022.0103.
    [2]
    CASULLERAS M, ZHANG IW, LÓPEZ-VICARIO C, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells, 2020, 9( 12): 2632. DOI: 10.3390/cells9122632.
    [3]
    HEO SK, YU HM, KIM DK, et al. LIGHT(TNFSF14) promotes the differentiation of human bone marrow-derived mesenchymal stem cells into functional hepatocyte-like cells[J]. PLoS One, 2023, 18( 8): e0289798. DOI: 10.1371/journal.pone.0289798.
    [4]
    ZHU BB, GAO FY, LI YX, et al. Serum cytokine and chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure[J]. Front Immunol, 2023, 14: 1133656. DOI: 10.3389/fimmu.2023.1133656.
    [5]
    YE C, LI WY, LI L, et al. Glucocorticoid treatment strategies in liver failure[J]. Front Immunol, 2022, 13: 846091. DOI: 10.3389/fimmu.2022.846091.
    [6]
    QIANG R, LIU XZ, XU JC. The immune pathogenesis of acute-on-chronic liver failure and the danger hypothesis[J]. Front Immunol, 2022, 13: 935160. DOI: 10.3389/fimmu.2022.935160.
    [7]
    FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: Prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67( 10): 1870- 1880. DOI: 10.1136/gutjnl-2017-314240.
    [8]
    MANTOVANI A, DINARELLO CA, MOLGORA M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity[J]. Immunity, 2019, 50( 4): 778- 795. DOI: 10.1016/j.immuni.2019.03.012.
    [9]
    DU LY, MA YJ, ZHOU SQ, et al. A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system[J]. Sci Rep, 2021, 11( 1): 1469. DOI: 10.1038/s41598-021-81019-8.
    [10]
    ZHANG Z, ZHU J, DOU Y. Effect of artificial liver plasma exchange combined with CRRT in the treatment of hepatitis B-related chronic acute liver failure complicated with acute renal failure and its impact on prognosis[J]. Clin Misdiagn Misther, 2023, 36( 10): 86- 90. DOI: 10.3969/j.issn.1002-3429.2023.10.019.

    张泽, 朱健, 窦燕. 人工肝血浆置换联合CRRT治疗乙肝相关慢加急性肝衰竭合并急性肾衰竭效果及对预后的影响[J]. 临床误诊误治, 2023, 36( 10): 86- 90. DOI: 10.3969/j.issn.1002-3429.2023.10.019.
    [11]
    WU CC, PENG WT, CHENG D, et al. Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis B liver failure[J]. J Clin Transl Hepatol, 2023, 11( 2): 433- 440. DOI: 10.14218/JCTH.2022.00106.
    [12]
    SHANG J, WANG MQ, WEN Q, et al. A novel prognostic model to predict outcome of artificial liver support system treatment[J]. Sci Rep, 2021, 11( 1): 7510. DOI: 10.1038/s41598-021-87055-8.
    [13]
    HUANG YD, JU T, ZHANG HF, et al. Lower level of IL-28A as a predictive index of the artificial liver support system in effective treatment of patients with HBV-ACLF[J]. J Clin Lab Anal, 2022, 36( 12): e24766. DOI: 10.1002/jcla.24766.
    [14]
    WANG L, XU WX, ZHU S, et al. Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure: A prospective study[J]. J Clin Transl Hepatol, 2023, 11( 4): 908- 917. DOI: 10.14218/JCTH.2022.00254.
    [15]
    HE J, ZHANG XP, ZHOU X, et al. Application of double plasma molecular adsorption system in children with acute liver failure[J]. Chin J Contemp Pediatr, 2021, 23( 2): 180- 185. DOI: 10.7499/j.issn.1008-8830.2010145.

    贺杰, 张新萍, 周雄, 等. 双重血浆分子吸附系统在儿童急性肝衰竭中的应用[J]. 中国当代儿科杂志, 2021, 23( 2): 180- 185. DOI: 10.7499/j.issn.1008-8830.2010145.
    [16]
    SEKANDARZAD A, WEBER E, PRAGER EP, et al. Cytokine adsorption in patients with acute-on-chronic liver failure(CYTOHEP)-a single center, open-label, three-arm, randomized, controlled intervention trial[J]. Trials, 2022, 23( 1): 222. DOI: 10.1186/s13063-022-06139-6.
    [17]
    AGARWAL B, CAÑIZARES RB, SALIBA F, et al. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on-chronic liver failure[J]. J Hepatol, 2023, 79( 1): 79- 92. DOI: 10.1016/j.jhep.2023.03.013.
    [18]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2024 version)[J]. J Clin Hepatol, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.
    [19]
    ZENG YY, GAN DK, ZHANG KG, et al. The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: A prospective cohort study[J]. Hepatol Int, 2024, 18( 5): 1540- 1554. DOI: 10.1007/s12072-024-10712-3.
    [20]
    BATEMAN RM, SHARPE MD, JAGGER JE, et al. 36th international symposium on intensive care and emergency medicine: Brussels, Belgium. 15-18 March 2016[J]. Crit Care, 2016, 20( Suppl 2): 94. DOI: 10.1186/s13054-016-1208-6.
    [21]
    RONCO C, CHAWLA L, HUSAIN-SYED F, et al. Rationale for sequential extracorporeal therapy(SET) in sepsis[J]. Crit Care, 2023, 27( 1): 50. DOI: 10.1186/s13054-023-04310-2.
    [22]
    RADMANIC MATOTEK L, ZIDOVEC-LEPEJ S, SALEK N, et al. The impact of liver steatosis on interleukin and growth factors kinetics during chronic hepatitis C treatment[J]. J Clin Med, 2024, 13( 16): 4849. DOI: 10.3390/jcm13164849.
    [23]
    ZHOU C, ZHANG N, HE TT, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure[J]. World J Gastroenterol, 2020, 26( 30): 4479- 4488. DOI: 10.3748/wjg.v26.i30.4479.
    [24]
    WU ZB, ZHENG YB, WANG K, et al. Plasma interleukin-6 level: A potential prognostic indicator of emergent HBV-associated ACLF[J]. Can J Gastroenterol Hepatol, 2021, 2021: 5545181. DOI: 10.1155/2021/5545181.
    [25]
    TARU V, SZABO G, MEHAL W, et al. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation[J]. J Hepatol, 2024, 81( 5): 895- 910. DOI: 10.1016/j.jhep.2024.06.016.
    [26]
    SCHWARZKOPF K, RÜSCHENBAUM S, BARAT S, et al. IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure[J]. Hepatol Commun, 2019, 3( 3): 392- 405. DOI: 10.1002/hep4.1303.
    [27]
    XIE ZB, DING L, LI YZ. Computed tomography image features under convolutional neural network algorithm in analysis of inflammatory factor level and prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. J Healthc Eng, 2021, 2021: 2110612. DOI: 10.1155/2021/2110612.
    [28]
    MOOKERJEE RP. Prognosis and biomarkers in acute-on-chronic liver failure[J]. Semin Liver Dis, 2016, 36( 2): 127- 132. DOI: 10.1055/s-0036-1583200.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (54) PDF downloads(14) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return